Brief: Cognition Therapeutics Awarded $2.14 Million In Supplemental Grant Funding From Nia To Support Sequel Clinical Trial
27/09/2022 12:59
Sept 27 (Reuters) - Cognition Therapeutics Inc CGTX.O :
* COGNITION THERAPEUTICS AWARDED $2.14 MILLION IN
SUPPLEMENTAL
GRANT FUNDING FROM NIA TO SUPPORT SEQUEL CLINICAL TRIAL
Source text for Eikon: ID:nGNX1xcQn1
Further company coverage: CGTX.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Cognition Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Cognition rises after FDA backs late-stage trial plan for dementia drug
Brief: Cognition Therapeutics Announces Issuance Of Composition Of Matter Patent, Extending Protection For Zervimesine (CT1812) Through 2045
Brief: Cognition Therapeutics Schedules A Type C Meeting With FDA To Align On Endpoints For Phase 3 Trial Of Zervimesine (Ct1812) In DLB